Literature DB >> 12649540

Involvement of TGF-beta signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis.

Yoshito Naiki1, Yasuhiro Maeda, Koki Matsuo, Satoru Yonekawa, Mika Sakaguchi, Ichiro Iwamoto, Hirofumi Hasegawa, Akihisa Kanamaru.   

Abstract

BACKGROUND: Functional failure of the peritoneal membrane is the most serious problem in long-term continuous ambulatory peritoneal dialysis (CAPD). Transforming growth factor-beta (TGF-ss) is one of the key mediators of fibrosis in some organs, and is thought to be involved in peritoneal alterations. In this study, we examined the role of TGF-beta1/TGF-ss receptors for human peritoneal mesothelial cells (HPMCs) and fibroblasts, and their interactions in CAPD patients.
METHODS: HPMCs were cultured for 48 h in a medium containing normal- dose glucose (7 mM), high-dose glucose (30 mM) and mannitol as an osmotic agent, equal to 30 mM glucose. Cell proliferation was observed using the Tetra Color One assay. The concentration of TGF-beta1 in culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA). The expression of TGF-ss receptor types I and II was observed by flow cytometry. HPMCs and fibroblasts were co-cultured and assayed using transwell inserts in order to identify the effects of the high-concentration glucose solution.
RESULTS: HPMC proliferation was inhibited by the high concentration of glucose but not by mannitol. The inhibition was abrogated by the neutralizing antibody for TGF-beta1. TGF-beta1 was induced by a high concentration of glucose but not by mannitol. The expression of both TGF-ss receptors was augmented in culture with the high concentration of glucose but not with mannitol. In the co-culture assay, the number of HPMCs was decreased and fibroblasts were significantly increased in culture with the high concentration of glucose.
CONCLUSIONS: A high concentration of glucose induced a large amount of TGF-beta1 and enhanced the expression of TGF-ss receptors. HPMCs were sensitive to TGF-beta1 in response to a high concentration of glucose. These data suggest that TGF-beta1 from HPMCs exposed to a high concentration of glucose down-regulates the proliferation of HPMCs and accelerates peritoneal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649540

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  6 in total

Review 1.  Mechanisms and interventions in peritoneal fibrosis.

Authors:  Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2011-09-21       Impact factor: 2.801

Review 2.  Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.

Authors:  Valentina Masola; Mario Bonomini; Silvio Borrelli; Lorenzo Di Liberato; Luigi Vecchi; Maurizio Onisto; Giovanni Gambaro; Roberto Palumbo; Arduino Arduini
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 3.  Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions.

Authors:  Mufazzal Ahmad; Hemal Shah; Theodori Pliakogiannis; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2006-09-27       Impact factor: 2.266

Review 4.  Protective measures against ultrafiltration failure in peritoneal dialysis patients.

Authors:  Anna Rita Aguirre; Hugo Abensur
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.

Authors:  Wei Gao; Zeng-Hong Li; Siqi Chen; Jimmy Yu-Wai Chan; Min Yin; Min-Juan Zhang; Thian-Sze Wong
Journal:  Oncotarget       Date:  2017-03-21

6.  ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose.

Authors:  Yong Chul Kim; Kyu Hong Kim; Sunhwa Lee; Ji-Won Jo; Jae Yoon Park; Mi-Seon Park; Bodokhsuren Tsogbadrakh; Jung Pyo Lee; Jae Wook Lee; Dong Ki Kim; Kook-Hwan Oh; In-Jin Jang; Yon Su Kim; Ran-Hui Cha; Seung Hee Yang
Journal:  J Cell Mol Med       Date:  2019-08-09       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.